That is last years abstract. The "update" will be made public at the conclusion of the conference. What we do know is as of the March investor presentation 208 patients had been evaluated in trials with PRO140. The latest June 1 PR stated: "To date, PRO 140 has been evaluated in more than 300 HIV patients in various studies."
News 
Market Data 
Discover 
AI
